UchiSearch
Brands and Their Owners
| Brand | Owner (click to sort) | Address | Description |
|---|---|---|---|
| BETTER MEDICINE BY DESIGN | MDS Proteomics Inc. | 251 Attwell Drive Toronto Ontario M9W 7H4 Canada | Systems and computer programs for assays in the diagnosis of diseases; systems and computer programs for chemical markers for disease states; systems and computer programs for performing diagnostics for diseases; systems and computer programs for determining targets for drugs; systems and computer programs for determining protein and peptide sequences; and scientific instruments, namely, mass spectrometers, automated sample preparers for mass spectrometers, and part and accessories for the foregoing, all for developing assays for the diagnosis of diseases, developing chemical markers for disease states, performing diagnostics for diseases, determining targets for drugs, and determining protein and peptide sequences.;Diagnosing diseases, developing chemical markers for disease states, determining targets for drugs determining protein and peptide sequences, and testing candidate drug compounds for activity; scientific research for others in the fields of the diagnosis of diseases, developing chemical markers for disease states, determining targets for drugs, determining protein and peptide sequences, testing candidate drug compounds for activity, and developing methodologies relating to the foregoing.; |
| MDSP | MDS Proteomics, Inc. | 75 International Boulevard Toronto M9W616 | Systems and computer programs for assays in the diagnosis of diseases; systems and computer programs for chemical markers for disease states; systems and computer programs for performing diagnostics for diseases; systems and computer programs for determining targets for drugs; systems and computer programs for determining protein and peptide sequences; and scientific instruments, namely, mass spectrometers, automated sample preparers for mass spectrometers, and part and accessories for the foregoing, all for developing assays for the diagnosis of diseases, developing chemical markers for disease states, performing diagnostics for diseases, determining targets for drugs, and determining protein and peptide sequences.;Diagnosing diseases, developing chemical markers for disease states, determining targets for drugs determining protein and peptide sequences, and testing candidate drug compounds for activity; scientific research for others in the fields of the diagnosis of diseases, developing chemical markers for disease states, determining targets for drugs, determining protein and peptide sequences, testing candidate drug compounds for activity, and developing methodologies relating to the foregoing.; |
| SIGNALING PROTEOMICS | MDS Proteomics Inc. | 251 Attwell Drive Toronto Ontario M9W 7H4 Canada | Systems and computer programs for assays in the diagnosis of diseases; systems and computer programs for chemical markers for disease states; systems and computer programs for performing diagnostics for diseases; systems and computer programs for determining targets for drugs; systems and computer programs for determining protein and peptide sequences; and scientific instruments, namely, mass spectrometers, automated sample preparers for mass spectrometers, and part and accessories for the foregoing, all for developing assays for the diagnosis of diseases, developing chemical markers for disease states, performing diagnostics for diseases, determining targets for drugs, and determining protein and peptide sequences.;Diagnosing diseases, developing chemical markers for disease states, determining targets for drugs determining protein and peptide sequences, and testing candidate drug compounds for activity; scientific research for others in the fields of the diagnosis of diseases, developing chemical markers for disease states, determining targets for drugs, determining protein and peptide sequences, identifying and/or determining protein-protein, protein-ligand, protein-nucleic acid, protein-small molecule or drug interactions, testing candidate drug compounds for activity, and developing methodologies relating to the foregoing.; |
Where the owner name is not linked, that owner no longer owns the brand |